Back to search

Article

Eye, Hepatobiliary, and Renal Disorders of Erlotinib in Patients with Non-Small-Cell Lung Cancer: A Meta-Analysis

2019-07-19

Abstract excerpt

<title>Abstract</title> <p>Background: Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors used to treat EGFR mutation positive non-small-cell lung cancer (NSCLC). Skin rash and diarrhea are well-known and common adverse events in patients receiving erlotinib, whereas other adverse events, including eye, liver, or renal disorders have not been evaluated adequately. This meta-analysi...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
5bc2e07f-1a20-5c86-91ec-ccc28e00ac66
DOI
10.21203/rs.2.11555/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Eye, Hepatobiliary, and Renal Disorders of Erlotinib in Patients with Non-Small-Cell Lung Cancer: A Meta-AnalysisDOI 10.21203/rs.2.11555/v1
Eye, hepatobiliary, and renal disorders of erlotinib in patients with non-small-cell lung cancer: A meta-analysis.Semantic proximity
Real-world use of osimertinib for epidermal growth factor receptor T790M-positive non-small cell lung cancer in Japan.Semantic proximity
Safety of EGFR-TKIs for EGFR mutation-positive non-small cell lung cancer.Semantic proximity
Erlotinib in combination with bevacizumab has potential benefit in non-small cell lung cancer: A systematic review and meta-analysis of randomized clinical trials.Semantic proximity
The Efficacy And Safety of Anlotinib Combined With Platinum-Etoposide Chemotherapy As First-Line Treatment For Extensive-Stage Small Cell Lung Cancer: A Chinese Multicenter Real-World StudySemantic proximity
Comparison of adverse events of erlotinib with those of gefitinib in patients with non-small cell lung cancer: a case-control study in a Japanese population.Semantic proximity
A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for OsimertinibSemantic proximity
[A review: drug-drug interactions of epithelial growth factor receptor-tyrosine kinase inhibitors].Semantic proximity
A review on adverse event profiles of epidermal growth factor receptor-tyrosine kinase inhibitors in nonsmall cell lung cancer patients.Semantic proximity
Efficacy and safety of icotinib in treating non-small cell lung cancer: a systematic evaluation and meta-analysis based on 15 studies.Semantic proximity
Erlotinib-induced skin rash. Pathogenesis, clinical significance and management in pancreatic cancer patients.Semantic proximity
Management of epidermal growth factor receptor tyrosine kinase inhibitor-related cutaneous and gastrointestinal toxicities.Semantic proximity
Select a neighboring publication to make it the new centre.